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Reply to the Editor:
In contrast to the studies quoted by Misawa
and Fuse, our investigation was aimed at
comparing the effect of normothermic ver-
sus hypothermic cardiopulmonary bypass
(CPB) on postoperative hemostasis and in-
flammatory activation. For this purpose,
patients were randomly assigned to one of
the two CPB temperatures (37°C vs 28°C),
and several inflammatory and coagulative
markers were evaluated at different time
intervals in the postoperative period. We
found no difference between the two
groups and concluded that, at least for our
CPB times, CPB temperature has no effect
on postoperative hemostasis and inflamma-
tory activation.
However, we congratulate Misawa and
Fuse for their interesting studies on the
effects of normothermic CPB on platelet
function and cytokine production and we
applaud their efforts to clarify the systemic
effects of normothermia.
Mario Gaudino, MD
Gianfederico Possati, MD
Department of Cardiac Surgery
Catholic University
Rome, Italy
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An economic evaluation of lung
transplantation
To the Editor:
In the March 2002 issue of this Journal,
Anyanwu and associates1 reported a prospec-
tive multicenter study about cost-effective-
ness and cost-utility for the different types of
lung transplantation. Although the study is an
important addition to the existing literature,
the method by which survival gain was cal-
culated and the impact on their sensitivity
analyses should be discussed further.
First, in the presented study Anyanwu and
associates1 calculated survival for the first 4
years from actual data and from years 4 to 15
by using a parametric Weibull model, in ac-
cordance with a previous analysis by our
group.2 At 15 years, the survival curve after
transplantation was cut off despite a survival
of at least 25%, depending on the type of
transplantation. Survival on the waiting list
declined to 0% after 11 years. For a valid
comparison of costs and effects of both con-
ditions from a lifetime perspective, a survival
curve after transplantation should be con-
structed with further extrapolation until a sur-
vival of 0%.3,4 Therefore the survival after
lung transplantation in the presented study
was underestimated, because prolonged sur-
vival beyond 15 years was neglected. A
rough calculation indicates that extrapolation
to 0% survival would amount to an estimated
additional survival gain after transplantation
of 2 years. This is why, in contrast to others,5
Anyanwu and colleagues1 did not find sur-
vival as a principal determinant of cost-effec-
tiveness in their sensitivity analyses.
Second, the survival curve for the wait-
ing list, to which the survival after lung
transplantation was compared, was not
constructed in accordance with previously
reported methods.3,4 In previous studies the
transplantation date was chosen as the
starting point for this comparison, because
it would be unrealistic to assume that dif-
ferences in survival occur before transplan-
tation. For the situation on the waiting list,
no real transplantation date exists, and a
fictitious transplantation moment should be
created (Figure 1). This moment should be
based on the average stay of patients on the
waiting list before transplantation (about
12 months in the study by Anyanwu and
associates1). However, day 0 was used as
the starting point for the waiting list. Ap-
plied to our own data, these two methods
result in a difference in the cumulative
number of life years on the waiting list of
0.5 years (17%).
Obviously, changing the method for the
calculation of survival gain will also influ-
ence the number of quality-adjusted life years
gained. It is possible that this would affect the
results of the sensitivity analyses with respect
Figure 1. Actual waiting list survival, fictitious waiting list survival, and survival after
lung transplantation (LTx) in Groningen lung transplant program, 1990 through 1995.
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to the effects of varying utility values and
posttransplantation maintenance costs as
well, thereby changing the conclusions for-
mulated by Anyanwu and associates.1
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Reply to the Editor:
We appreciate the comments of Ouwens and
colleagues regarding our article on economic
evaluation of lung transplantation. These
comments highlight a major limitation of any
economic study, which is the reliance on
assumptions. Economic studies of therapies
that have long-term benefits necessarily
make predictions of future events. Because
the future is always unknown, assumptions
have to be imposed to allow modeling of data
into the future. Methods used for modeling
data vary from study to study. For this reason
most economic studies include sensitivity
analyses that examine the impact of alterna-
tive assumptions on the study conclusions.
Ouwens and colleagues propose two al-
ternative approaches to examining the bene-
fits of lung transplantation—assessing life-
time benefits and imposing a fictitious
“transplant date” for the waiting list survival.
Although it is true that the benefits of trans-
plantation will continue beyond the 15-year
time frame of our study, we elected to restrict
benefits to those occurring in the first 15
years. We chose to restrict our analysis to 15
years because the robustness of the conclu-
sions diminish as predictions go further over
the horison. The Weibull method used to
predict long-term survival is based on the
observed short- to medium-term survival of a
cohort of patients. In our study we predicted
long-term survival on the basis of observed
4-year survival. We believe that this method
overestimates survival after transplantation,
however, because it does not allow for late
deaths resulting from long-term complica-
tions of immunosuppression and chronic
graft rejection or failure. For example, ex-
trapolation of our data to 20 years suggests
that 25% of patients will still be alive 20
years after lung transplantation, a figure that
we consider overly optimistic. Indeed, if we
were to continue our survival curve until
there were no survivors, as suggested by Ou-
wens and colleagues, we would end up with
several patients surviving to 100 years of age
after having received a lung transplant.
Although such scenarios are statistically
correct, we do not think that they are clini-
cally plausible. Furthermore, any benefits af-
ter 15 years would be modest, because dis-
counting means that future benefits carry less
weight than do immediate benefits. For ex-
ample, if we had examined benefits through
20 rather than 15 years, the benefit of single-
lung transplantation would only improve
from 2.1 to 2.2 quality-adjusted life years.
Assumptions also have to be imposed on
defining the start of the waiting list episode,
because there is no objective point to define
as the start of medical treatment on the wait-
ing list. Unlike transplantation, there is no
medical intervention or event that can be
ascribed to a particular day. There is at
present no clear definition of the time of
onset of end-stage lung disease, nor is there
an objective method of deciding the point at
which a patient should be listed for transplan-
tation. Patients are listed at different stages of
the disease process, depending on all sorts of
patient-related, logistic, and local factors. We
argue that the date a patient is registered on
the waiting list is itself a robust measure
neither of onset of end-stage lung disease nor
of the need for lung transplantation. Methods
of ascribing day 0 for waiting list survival (as
a proxy for survival without transplantation)
are therefore arbitrary and are bound to vary
from study to study. As demonstrated by
Ouwens and colleagues, different methods of
ascribing day 0 for waiting list cohorts sim-
ply result in a small shift of the whole sur-
vival curve; they do not change its profile.
Although the approaches suggested by
Ouwens and colleagues are valid alternatives
to the methods that we used, they would not
affect our study conclusions. We believe that
the explanation for the modest benefit we
found with lung transplantation lies not in our
mathematical assumptions or techniques but
in the relatively high early mortality after
lung transplantation, which is observed on a
global scale.1 Our findings are indeed not
unique; analyses of large North American
databases have also questioned the notion
that lung transplantation results in large sur-
vival improvements.2,3
A. C. Anyanwu
A. J. Murday
Glasgow Royal Infirmary
Glasgow, United Kingdom
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To close or not to close?
To the Editor:
In their article “Intrapericardial Left Pneu-
monectomy after Induction Chemotherapy:
The Risk of Cardiac Herniation,” Baisi and
associates1 reported the use of a polytetra-
fluoroethylene patch for closure of the peri-
cardium after herniation of the heart and
recommended routine use of a patch for
closure of pericardium without tension. I
agree wholeheartedly that pericardial clo-
sure, if done at all, must always be without
tension. However, pericardium does not al-
ways have to be closed. When lung resec-
tion for cancer requires excision of part of
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